Skip to content
TrialScanner

NCT04588428

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Phase 2CompletedINOLead

Registry record

Lead sponsor
Inovio Pharmaceuticals
Conditions
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Primary completion
Jan 19, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04588428 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04588428: Safety, Tolerability and... | TrialScanner